A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Fasiglifam (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda; Takeda Global Research and Development Center
- 27 Dec 2013 Status changed from recruiting to discontinued, according to a Takeda media release.
- 15 Jun 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2013-000007-17).
- 10 Jun 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.